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BACKGROUND: Autologous stem cell transplantation is
an established treatment option for patients with multiple
myeloma (MM) or non-Hodgkinʼs lymphoma (NHL).
STUDY DESIGN AND METHODS: In this prospective
multicenter study, 147 patients with MM were compared
with 136 patients with NHL regarding the mobilization
and apheresis of blood CD34+ cells, cellular composition
of infused blood grafts, posttransplant recovery, and
outcome.
RESULTS: Multiple myeloma patients mobilized CD34+
cells more effectively (6.3 × 106/kg vs. 3.9 × 106/kg,
p = 0.001). The proportion of poor mobilizers (peak blood
CD34+ cell count <20 × 106/L) was higher in NHL
patients (15% vs. 3%, p < 0.001). Plerixafor was added
to rescue the mobilization failure in 17 MM patients
(12%) and in 35 NHL patients (26%; p = 0.002). The
infused grafts contained more natural killer (NK) and
CD19+ cells in MM patients. Blood platelet and NK-cell
counts were higher in MM patients posttransplant. Early
treatment-related mortality was low in both groups, but
NHL patients had a higher late (>100 days) nonrelapse
mortality (NRM; 6% vs. 0%, p = 0.003).
CONCLUSIONS: Non-Hodgkinʼs lymphoma and MM
patients differ in terms of mobilization of CD34+ cells,
graft cellular composition, and posttransplant recovery.
Thus, the optimal graft characteristics may also be
different.
ABBREVIATIONS: 7-AAD = 7-aminoactinomycin; auto-SCT(s) = autologous
stem cell transplantation(s); B-CD34+ = blood CD34+ (count); GOA Study =
Graft and Outcome in Autologous Stem Cell Transplantation Study; HDT =
high-dose therapy; ICU = intensive care unit; MM = multiple myeloma; NHL
= non-Hodgkinʼs lymphoma; NRM = nonrelapse mortality; OS = overall
survival; PFS = progression-free survival; TRM = treatment-related mortality.
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M
ultiple myeloma (MM) and non-Hodgkinʼs
lymphoma (NHL) are the most common
indications for autologous stem cell trans-
plantation (auto-SCT).1 The majority of
transplant-eligible MM patients receive auto-SCT after
induction therapy, whereas in NHL patients auto-SCT might
be considered after first-line therapy for patients with man-
tle cell lymphoma or those with aggressive peripheral T-cell
lymphoma. In patients with diffuse large B-cell lymphoma
auto-SCT is usually considered after a relapse, except in
those patients not achieving complete remission after first-
line chemoimmunotherapy.2
Approximately 99% of all auto-SCTs are performed
with blood grafts.1 Granulocyte–colony-stimulating factor
(G-CSF) alone or combined with chemotherapy are com-
monly used as mobilizing agents. More recently plerixafor
has become available especially in case of insufficient mobi-
lization. Besides the mobilization method used, also several
patient-related factors (e.g., age, disease, previous therapy,
marrow infiltration) affect both the capacity to mobilize
CD34+ cells for transplant purposes and the cellular compo-
sition of the grafts collected.3–7 A significant proportion of
patients fail to mobilize stem cells sufficiently to support
high-dose therapy (HDT). In general, NHL patients carry a
higher risk of poor mobilization than MM patients,8,9 but in
some studies this difference has not been detected.10
An adequate number of CD34+ cells has remained the
most important marker of graft quality in the autologous
setting. Higher graft CD34+ cell content has been linked
with faster platelet (PLT) and neutrophil recovery after
HDT.11,12 In some retrospective studies higher graft CD34+
cell count has also been associated with improved
progression-free survival (PFS) and even overall survival
(OS).13–16 A minimum collection target of 2.0 × 106/kg
CD34+ cells has been proposed,17 but the optimal graft
CD34+ count for hematologic recovery and posttransplant
outcome is still debatable.5,18
Higher total lymphocyte and natural killer (NK)-cell
counts in the grafts have been linked with faster immune
recovery and also better PFS and OS in both MM and NHL
patients.19,20 An antitumor effect mediated by NK cells or T
lymphocytes has been proposed as a possible reason for the
observed survival benefit.18,21,22 MM and NHLs have differ-
ent biologic features and treatments. In practice, there are
also some differences in the mobilization of the blood grafts
according to the diagnosis. There is a lack of data compar-
ing graft cellular composition and hematologic and immune
recovery posttransplant between MM and NHL patients.
Limited comparative data are also available on post-
transplant complications, including nonrelapse mortal-
ity (NRM).
The aim of the prospective multicenter Graft and Out-
come in Autologous Stem Cell Transplantation (GOA) study
was to investigate the effects of different mobilization
methods on collected blood graft cellular composition and
to evaluate the effects of infused graft cellular composition
on hematologic and immunologic recovery as well as PFS
and OS posttransplant. In this analysis based on the patients
of the GOA study we compared MM patients with NHL
patients regarding mobilization and apheresis of CD34+
cells, cellular composition of infused blood grafts, recovery
of blood counts, and complications posttransplant.
PATIENTS AND METHODS
Patients
Between May 2012 and December 2016, altogether 283
patients receiving their first auto-SCT at the university hospi-
tals of Kuopio, Oulu, Tampere, and Turku in Finland were
included in the prospective observational GOA study. The
population consisted of 147 patients with MM and
136 patients with NHL. A proportion of the MM patients
(n = 40, 29%) also participated in the randomized MM-02
study by the Finnish Myeloma Group, in which the patients
received mobilization with either low-dose cyclophosphamide
(CY) plus G-CSF or G-CSF alone in a randomized fashion
after three cycles of induction treatment with lenalidomide,
bortezomib, and dexamethasone followed by a single auto-
SCT and lenalidomide maintenance23,24 (NCT01790737). The
characteristics of MM and NHL patients included in the GOA
study are presented in Table 1.
Mobilization and collection of blood grafts
All NHL patients were mobilized with chemotherapy plus
G-CSF, whereas MM patients received either low-dose CY
(2 g/m2) plus G-CSF (n = 90, 61%) or G-CSF alone (n = 57,
39%) as mobilization therapy. The G-CSF used after mobi-
lizing chemotherapy in NHL patients was a single injection
with either 6 mg (n = 54, 40%) or 12 mg (n = 26, 19%)
pegfilgrastim, 10 μg/kg filgrastim daily until the completion
of apheresis (n = 41, 30%), or a single 6-mg dose of
lipegfilgrastim (n = 15, 11%) depending on institutional
preferences. In MM patients, the G-CSF used in chem-
omobilization was either 5 μg/kg/day filgrastim until the
completion of graft collection (n = 70, 47%) or a single 6-mg
dose of pegfilgrastim (n = 20, 14%). A higher filgrastim dose
of 10 μg/kg was used in G-CSF alone mobilized MM
patients (n = 57, 39%). The blood CD34+ count (B-CD34+)
was analyzed in each university laboratory center daily dur-
ing the stem cell collection period. A minimum collection
target of at least 2 × 106/kg CD34+ cells per transplant was
used in all transplant centers. For the subgroup of patients
participating in the MM-02 study, a higher collection target
of 3 × 106/kg CD34+ cells for a single transplant was used.
If a second transplant was an option, the collection target
was 4 × 106/kg CD34+ cells, and for the MM-02 patients,
6 × 106/kg CD34+ cells. Plerixafor was added to the mobili-
zation preemptively in case of insufficient mobilization
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(B-CD34+ < 10 × 106/L despite increasing white blood cell
[WBC] count >5 × 109/L, n = 38). If the previous apheresis
yields were considered inadequate and the B-CD34+ counts
were declining, plerixafor was also given (n = 14).
Kuopio University Hospital used initially a COBE
Spectra AutoPBSC apheresis device (Terumo BCT), but
from April 2013 onward a different apheresis system was
used (Spectra Optia, Software 7.2, Terumo BCT). In Oulu
and Tampere University Hospitals the Spectra Optia aphe-
resis system was used throughout the study. Turku Univer-
sity Hospital used a different apheresis system (COM.TEC
Fresenius blood cell separator, Fresenius Hemo Care
GmbH). The blood volume circulated per apheresis was
2.3 to 3.0 times the estimated blood volume of the patient.
The number of collected CD34+ cells was analyzed after
each apheresis with a flow cytometry using an ISHAGE
protocol25 at the stem cell laboratory of each university
hospital.
Graft analysis
Two 0.5-mL tubes were taken from each apheresis product
for subsequent graft analysis. The specimens were pre-
served the same way as the grafts. Dimethyl sulfoxide was
added for final concentration of 10% to protect the cells
from stress or death during cryopreservation. A freezer with
controlled-rate freezing in liquid nitrogen was used. The
cryopreserved graft specimens were sent overnight from
Oulu, Tampere, and Turku University Hospitals to the
Department of Clinical Microbiology, University of Eastern
Finland, Kuopio, for the analysis of graft cellular
composition.
A single experienced flow cytometrist (AR) analyzed the
graft specimen after thawing using a flow cytometry system
(FACSCanto, Becton Dickinson). The antibodies used for
CD34+ cells and subclasses were CD34, CD38, CD133, and
CD45. The antibodies were delivered by Becton Dickinson,
except for CD133, which came from Miltenyi Biotech GmbH.
7-Aminoactinomycin (7-AAD) was used to distinguish the via-
ble CD34+ cells. Total T-cell, B-cell, and NK-cell counts as well
as the CD3+CD4+ and CD3+CD8+ lymphocyte subsets in the
grafts were determined using both CD3/CD8/CD45/CD4 and
CD3/CD16+CD56/CD45/CD19 reagents (BD Multitest, Becton
Dickinson) with tubes (BD Trucount, Becton Dickinson).
In the majority of MM patients (100/147, 68%) a part of
the collected graft was kept cryopreserved to support a pos-
sible second HDT in the future at relapse or disease pro-
gression. In five NHL patients (4%) with a large median
15.5 × 106/kg (range 7.2 × 106/kg-25.5 × 106/kg) CD34+ cell
total apheresis yield only part of the collected graft was
infused after HDT whereas all other NHL patients received
the whole collected graft after HDT.
HDT and posttransplant follow-up
All MM patients received 200 mg/m2 high-dose melphalan
as HDT on Day –2 followed by graft infusion on Day 0. Most
of the NHL patients (117/137, 85%) received BEAM
(300 mg/m2 carmustine on Day −6, 100 mg/m2 etoposide
b.i.d. from Day −5 to Day −2, 200 mg/m2 cytarabine
b.i.d. from Day −5 to Day −2, and 140 mg/m2 melphalan on
Day −2). Twelve NHL patients (9%) with primary central
nervous system lymphoma were given a combination of car-
mustine (400 mg/m2 on Day −6) and thiotepa (5 mg/kg
b.i.d. on Day −5 and Day −4) as HDT and seven NHL
patients (5%) received BEAC (300 mg/m2 carmustine on Day
−7, 100 mg/m2 etoposide b.i.d. from Day −6 to Day −3,
100 mg/m2 cytarabine b.i.d. from Day −6 to Day −3, and
1500 mg/m2 CY from Day −6 to Day −3).
The G-CSF usage posttransplant was registered: 98% of
the NHL patients received G-CSF after the graft infusion
compared to 72% of the MM patients (p < 0.001).
Depending on institutional preferences, MM patients were
given either 5 μg/kg filgrastim daily (n = 63, 60%) or a single
6-mg dose of pegfilgrastim on Day +1 after graft infusion
TABLE 1. Patient, disease, and mobilization
characteristics in the GOA study*
Variable
MM NHL
Significancen = 147 n = 137
Sex (male/female) 78/69 85/52 0.126
Age (years), median
(range)
64
(49-73)
62
(19-73)
<0.001
MM patients
Paraprotein type
IgG 85 (58)
IgA 34 (23)
IgM 1 (0.4)
Light chain 27 (18)
NHL patients
Histology
DLBCL† 68 (50)
MCL 37 (27)
PTCL 18 (13)
FL 13 (10)
Burkitt lymphoma 1 (1)
Mobilization
CT + G-CSF 90 (61) 137
(100)
<0.001
G-CSF alone 57 (39) <0.001
Use of plerixafor 17 (12) 35 (26) 0.002
Mobilization
chemotherapy‡
HD-AraC 57 (41)
DHAP 44 (32)
ICE 11 (5)
CY§ 90 (61) 4 (3)
Other 21 (15)
* Data are reported as number (%), unless otherwise
specified.
† Including 12 patients with primary CNS lymphoma.
‡ Given to at least 10 patients.
§ 2 g/m2 low-dose CY for MM patients and 4 g/m2 for NHL
patients.
DLBCL = diffuse large B-cell lymphoma; MCL = mantle cell lym-
phoma; PTCL = peripheral T-cell lymphoma; FL = follicular lym-
phoma; CT + G-CSF = chemotherapy + G-CSF; HD-AraC =
high-dose cytarabine; DHAP = dexamethasone, high-dose
cytarabine, cisplatin; ICE = ifosfamide, carboplatin, etoposide.
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(n = 42, 40%). Respectively, NHL patients received either
5 μg/kg filgrastim daily (n = 27, 20%), pegfilgrastim (n = 72,
54%), or a single 6-mg dose of lipegfilgrastim on Day +1
(n = 34, 26%).
Platelet engraftment was defined as the first of 3 consec-
utive days with PLT count of more than 20 × 109/L without
PLT transfusions after the graft infusion (Day 0). Neutrophil
engraftment was defined as the first of 3 consecutive days
with neutrophil count of more than 0.5 × 109/L, respec-
tively. Complete blood counts were evaluated on Day
+15 and 1, 3, 6, and 12 months after auto-SCT. In addition,
in a proportion of the patients, blood lymphocyte subsets
were analyzed at 1, 3, and 6 months posttransplant by using
both CD3/CD8/CD45/CD4 and CD3/CD16+CD56/CD45/
CD19 reagents (BD Multitest, Becton Dickinson) with tubes
(BD Trucount, Becton Dickinson). This analysis was per-
formed in MM patients participating in the MM-02 study
(n = 40) as well as in 48 consecutive NHL patients treated in
the Kuopio University Hospital catchment area. In the case
of a disease relapse or progression the follow-up of the
hematologic and immune recovery was discontinued.
Non-Hodgkinʼs lymphoma patients treated at the Kuo-
pio University Hospital (n = 106) were given oral ciprofloxa-
cin as an antimicrobial prophylaxis (500 mg b.i.d.) starting
2 days before the graft infusion until the onset of febrile neu-
tropenia and broad-spectrum antibiotics or until neutrophil
recovery of at least 1.0 × 109/L. MM patients did not receive
antibiotic prophylaxis. Cotrimoxazole was used for 4 months
after auto-SCT as prophylaxis against Pneumocystis jiroveci.
In the case of allergy or intolerance to sulfonamides, monthly
inhalations of pentamidine were used instead.
Infections during the first year after auto-SCT were
recorded. Episodes of febrile neutropenia early after auto-
SCT with a definition of a temperature over 38.0°C and neu-
trophil count of less than 0.5 × 109/L were evaluated. Positive
blood culture findings, pneumonias, and intensive care unit
(ICU) admissions during the hospitalization period after HDT
were recorded as well as data on later infections caused by
P. jirovecii, varicella zoster, or other infections requiring
readmission into hospital. Early treatment-related mortality
(TRM) was defined as a death within 100 days after auto-SCT
from other reasons than malignancy per se. NRM was
defined as a death of any cause prior to disease progression
or relapse.
Statistical analysis
Analyses were performed in all patients and between the
groups. Statistical analysis and calculations were performed
with computer software (SPSS Statistics Version 25, IBM
Corp.). Continuous variables are presented as medians and
ranges. The Mann-Whitney U test and Pearsonʼs chi-square
test were used. All p values were two-tailed. p values of less
than 0.05 were considered as significant.
Ethics
The Research Ethics Committee of North Savo Hospital Dis-
trict approved the GOA study (13/2012) and the FMG MM-
02 study (51/2012). All patients gave their written informed
consent before enrollment to the study.
RESULTS
Mobilization and collection of CD34+ cells
The peak B-CD34+ count was higher in MM patients than in
NHL patients (median, 64 × 106/L vs. 39 × 106/L, p < 0.001).
The proportion of poor mobilizers (peak B-CD34+ count
<20 × 106/L) was significantly higher in NHL patients (15%
vs. 3%, p < 0.001). In contrast, the proportion of “super
mobilizers” (peak B-CD34+ count >100 × 106/L) was higher
in MM patients (28% vs. 16%, p = 0.02). Plerixafor was added
to the mobilization in 17 MM patients (12%) and in 35 NHL
patients (26%; p = 0.002). The median B-CD34+ was higher
among MM patients before (8 × 106/L vs. 6 × 106/L,
p = 0.001) as well as after plerixafor injection (19 × 106/L
vs. 12 × 106/L, p = 0.01). The median (range) plerixafor dose
was 0.26 (0.11-0.39) mg/kg in MM patients and 0.25
(0.15-0.32) mg/kg in NHL patients (p = 0.532). The median
(range) number of plerixafor injections was 1 (1-2) in MM
patients and 2 (1-4) in NHL patients (p = 0.043). The median
number of CD34+ cells collected (6.3 × 106/L vs. 3.9 ×
106/kg, p < 0.001) was higher in MM patients. The number of
CD3+ lymphocytes, CD3+CD4+ cells, NK cells and CD19+ B
lymphocytes were all significantly higher in MM patients.
The detailed mobilization and apheresis data are presented
in Table 2.
Cellular composition of infused grafts
The median amount of viable CD34+ cells (with 7-AAD)
in the infused graft was 2.35 × 106/kg in the MM group
and 2.5 × 106/kg in the NHL group (p = 0.02). In MM
patients, the grafts contained more NK cells (10.1 × 106/L
vs. 6.1 × 106/kg, p = 0.01) and CD19+ B lymphocytes
(1.69 × 106/L vs. 0.00 × 106/kg, p < 0.001; Table 3). In the
subgroup of patients mobilized with CY plus G-CSF, the
blood grafts of MM patients contained fewer CD3+ cells,
CD3+CD4+, CD3+CD8+, and NK cells (Table 3) than those
of NHL patients.
Posttransplant follow-up
The neutrophil engraftment posttransplant was faster in
NHL patients (9 days vs. 12 days, p < 0.001) but the median
time to PLT engraftment was 12 days in the both groups
(p = 0. 686). During the auto-SCT hospitalization period
88% (n = 119) of the NHL patients had febrile neutropenia
compared to 79% (n = 116) in the MM group (p = 0.06).
There was no difference between the groups regarding the
incidence of bacteremia after auto-SCT (n = 23, 17%
vs. n = 27, 18%, p = 0.748). In patients with bacteremia,
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Gram-positive predominance in blood culture findings was
observed in both NHL (n = 18/23, 78%) and MM patients
(n = 15/27, 56%, p = 0.083). NHL patients had more ICU
admissions (n = 5, 4% vs. n = 0, 0%, p = 0.02) and a longer
median duration of hospitalization(22 days vs. 18 days,
p < 0.001).
During the first year after auto-SCT the readmission
rate due to infections did not differ between the groups
(22% vs. 24%, p = 0.768). There were five verified
Pneumocystis infections in the NHL group (4%) compared
to one in the MM group (1%, p = 0.08). Varicella zoster was
reported in 10% of the patients in the both groups
(p = 0.940). Early TRM was low in the both groups with two
deaths in the NHL group (1.5%) and no deaths at all among
the MM patients (p = 0.14). Late (>100 days) NRM was sig-
nificantly higher in NHL patients (n = 8, 6%) than in MM
patients (n = 0, 0%; p = 0.003). Infections were the leading
cause of NRM (4/10, 40%).
TABLE 2. Comparison of mobilization and graft collection data between all MM and NHL patients and between
chemomobilized (CY + G-CSF) MM and NHL patients*
Variable NHL All MM patients†
p value‡
(vs. NHL) MM† (CY + G-CSF)
p value‡
(vs. NHL)
WBC count at the time of first
apheresis (×109/L)
12 (0.9-116.2); 136 17.4 (1.1-82.4); 143 0.007§ 10.0 (1.1-79.6); 90 0.029§
B-CD34+ cells at the time of first
apheresis (×106/L)
30 (5-538); 136 57 (10-415); 143 <0.001§ 75 (11-415); 89 <0.001§
CD34+ cell yield with first
apheresis (×106/kg)
2.3 (0.1-25.5); 136 3.7 (0.2-17.9); 147 <0.001§ 4.5 (0.7-17.8); 90 <0.001§
Peak B-CD34+ count (×106/L) 39 (6-538); 136 64 (12-415); 147 <0.001§ 93 (12-415); 90 <0.001§
Peak B-CD34+ count <20 × 106/L 20 (15) 4 (3) <0.001§ 2 (2) 0.002§
Peak B-CD34+ count >100 × 106/L 22 (16) 41 (28) 0.018§ 38 (42) <0.001§
Total collected CD34+ cell yield
(×106/kg)k
3.9 (1.6-25.5); 136 6.3 (2.0-17.9); 147 <0.001§ 7.4 (2.0-17.9); 90 <0.001§
Total collected CD3+ yield
(×106/kg)¶
88.8 (0.7-1022.5); 128 123.9 (5.5-1576.2); 124 0.001§ 71.1 (5.5-354.2); 72 0.374
Total collected CD3+CD4+ yield
(×106/kg)¶
44.2 (0.5-365.3); 128 71.2 (3.4-608.9); 124 <0.001§ 45.1 (3.4-290.3); 72 0.490
Total collected CD3+CD8+ yield
(×106/kg)¶
35.1 (0.4-644.9); 128 44.9 (1.5-1213); 124 0.084 24.2 (1.5-133.9); 72 0.025§
Total collected NK-cell yield
(×106/kg)¶
6.1 (0.1-56.9); 128 15.6 (0.5-748.9); 124 <0.001§ 6.2 (0.5-70.9); 72 0.860
Total collected CD19+ cell yield
(×106/kg)¶
0.0 (0.0-100.2); 128 2.6 (0.0-97.0); 124 <0.001§ 1.6 (0.0-66.6); 72 <0.001§
Number of apheresis procedures 2 (1-4); 136 2 (1-4); 147 0.080 2 (1-4); 90 0.717
* Data are presented as median (range); number of observations or number (%).
† Most MM patients had a higher minimum CD34+ cell collection target (4.0 × 106/kg).
‡ Compared to the NHL patient group.
§ Statistically significant (p < 0.05)
k Measured before cryopreservation by flow cytometry.
¶ Measured after thawing by flow cytometry.
TABLE 3. Comparison of cellular composition of the infused grafts between all MM and NHL patients and between
chemomobilized (CY + G-CSF) MM patients and NHL patients
Blood graft content (×106 cells/kg)§ NHL* All MM patients* p value† MM (CY + G-CSF)* p value†
CD34+ cells without 7-AAD 3.2 (0.8-16.5); 128 3.1 (0.6-8.7); 127 0.182 3.5 (1.6-8.7); 73 0.519
CD34+ cells with 7-AAD 2.5 (0.6-14.3); 129 2.4 (0.2-7.2); 127 0.020‡ 2.8 (0.7-7.2); 73 0.795
CD34+CD133+CD38– cells 0.07 (0.006-0.3); 129 0.06 (0.005-0.6); 127 0.099 0.07 (0.007-0.6); 73 0.955
CD3+ cells 88.8 (0.7-1022.5); 128 78.8 (2.8-1576.2); 125 0.947 41.3 (2.8-354.2); 72 <0.001‡
CD3+CD4+ cells 44.2 (0.5-365.3); 128 48.5 (2.1-474.7); 125 0.279 25.6 (2.1-290.3); 72 0.004‡
CD3+CD8+ cells 34.3 (0.4-644.9); 128 25.5 (0.8-1213.9); 125 0.344 13.8 (0.8-90.7); 72 <0.001‡
CD19+ cells 0.0 (0.0-100.2); 128 1.7 (0.0-66.6); 125 <0.001‡ 0.9 (0.0-66.6); 72 <0.001‡
NK cells 6.1 (0.05-56.9); 128 10.1 (0.24-748.9); 125 0.011‡ 3.3 (0.2-35.5); 72 0.005‡
* Data are presented as median (range); number of observations.
† Compared to the NHL patient group.
‡ Statistically significant (p < 0.05).
§ Measured after thawing by flow cytometry.
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TABLE 4. Comparison of hematologic recovery after auto-SCT between MM and NHL patients
Variable MM* NHL* p value
Neutrophil engraftment (days) 12 (9-30); 147 9 (0-30); 136 <0.001†
PLT engraftment (days) 12 (0-55); 145 12 (0-201); 133 0.605
Hb (g/L)
+1 month 116 (80-143); 141 112 (64-140); 112 0.002†
+3 months 123 (89-156); 143 122 (86-158); 118 0.252
+6 months 126 (91-159); 132 129 (70-160); 110 0.729
+12 months 131 (102-161); 114 134 (96-176); 96 0.058
WBCs (×109/L)
+15 days 3.0 (0.3-126.0); 144 5.0 (0.3-26.9); 135 <0.001†
+1 month 4.9 (2.1-26.8); 141 5.0 (1.6-12.0); 132 0.781
+3 months 4.5 (1.7-13.7); 143 4.2 (1.9-40.0); 118 0.065
+6 months 4.4 (1.7-13.4); 132 4.4 (1.3-10.2); 110 0.894
+12 months 4.8 (0.7-9.0); 113 5.2 (2.4-11.1); 96 0.170
Neutrophils (×109/L)
+15 days 1.6 (0.06-9.0); 132 3.4 (0.2-20.7); 127 <0.001†
+1 month 2.1 (0.4-23.7); 127 2.1 (0.07-9.7); 130 0.798
+3 months 2.1 (0.5-7.6); 136 1.5 (0.1-11.2); 116 <0.001†
+6 months 2.0 (0.2-9.8); 122 2.0 (0.4-10.7); 101 0.610
+12 months 2.4 (0.7-5.8); 98 2.4 (0.6-9.7); 88 0.189
Lymphocytes (×109/L)
+15 days 0.6 (0.07-3.7); 111 0.6 (0.04-4.2); 117 0.596
+1 month 1.6 (0.5-6.1); 108 1.8 (0.4-8.1); 120 0.593
+3 months 1.6 (0.4-6.5); 125 1.8 (0.4-5.5); 108 0.263
+6 months 1.5 (0.4-3.8); 107 1.8 (0.4-4.8); 97 0.063
+12 months 1.6 (0.6-4.7); 88 1.8 (0.4-5.4); 82 0.418
PLT count (×109/L)
+15 days 57 (9-431); 144 54 (4-296); 135 0.897
+1 month 184 (12-633); 140 133 (10-343); 131 <0.001†
+3 months 184 (27-362); 143 143 (10-357); 117 <0.001†
+6 months 192 (66-385); 132 164 (14-328); 109 0.002†
+12 months 196 (62-417); 114 177 (23-326); 95 0.023†
* Data are reported as median (range); number of observations.
† Statistically significant (p < 0.05).
TABLE 5. Comparison of immune recovery after auto-SCT between MM and NHL patients
Variable MM* NHL* p value
CD3+ cell count (×109/L)
+1 month 1.1 (0.3-5.9); 27 1.2 (0.2-4.4); 48 0.77
+3 months 1.2 (0.2-2.6); 39 1.5 (0.3-4.8); 32 0.04†
+6 months 1.0 (0.4-1.9); 34 1.3 (0.3-4.0); 29 0.06
CD4+ cell count (×109/L)
+1 month 0.3 (0.1-2.0); 27 0.3 (0.05-1.5); 48 0.43
+3 months 0.3 (0.1-0.8); 39 0.4 (0.1-0.9); 32 0.09
+6 months 0.3 (0.1-0.7); 34 0.3 (0.1-0.7); 30 0.77
CD8+ cell count (×109/L)
+1 month 0.8 (0.2-5.4); 27 0.9 (0.1-3.9); 48 0.38
+3 months 0.9 (0.2-2.2); 39 1.1 (0.1-4.2); 32 0.06
+6 months 0.6 (0.2-1.6); 34 0.9 (0.2-3.4); 29 0.03†
CD19+ cell count (×109/L)
+1 month 0.0 (0.0-0.1); 27 0.0 (0.0-0.0); 47 <0.001†
+3 months 0.1 (0.0-0.4); 39 0.0 (0.0-0.3); 32 <0.001†
+6 months 0.1 (0.0-0.5); 34 0.0 (0.0-0.3); 29 <0.001†
NK-cell count (×109/L)
+1 month 0.4 (0.1-0.8); 27 0.2 (0.02-0.7); 48 0.03†
+3 months 0.2 (0.1-0.9); 39 0.2 (0.05-0.9); 32 0.15
+6 months 0.23 (0.10-0.75); 34 0.17 (0.03-1.14); 29 0.02†
CD4+/CD8+ ratio
+1 month 0.4 (0.0-1.2); 27 0.3 (0.1-1.1); 48 0.34
+3 months 0.3 (0.0-1.3); 39 0.3 (0.1-1.1); 32 1.0
+6 months 0.4 (0.0-1.3); 34 0.4 (0.1-1.3); 29 0.59
* Data are presented as median (range); number of observations. Reference values of blood flow cytometry reported by the Laboratory Cen-
ter of Eastern Finland: B-T-CD3, 0.85 × 109 to 2.28 × 109/L; B-CD19, 0.12 × 109 to 0.43 × 109/L; B-T-CD4, 0.458 × 109 to 1.406 × 109/L; B-T-
CD8, 0.24 × 109 to 0.98 × 109/L; B-NK, 0.08 × 109 to 0.57 × 109/L.
† Statistically significant (p < 0.05).
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Hematologic and immune recovery after auto-SCT
The median hemoglobin (Hb) level at 1 month after auto-
SCT was higher among MM patients (116 vs. 112 g/L,
p = 0.001). The pace of WBC and neutrophil recovery was
faster in NHL patients on Day +15 after the graft infusion.
Later the neutrophil level decreased in the NHL group and
was significantly lower at 3 months posttransplant. The lym-
phocyte recovery was comparable between the groups. The
PLT count was higher in the MM group from 1 month until
1 year after auto-SCT. Data on posttransplant hematologic
recovery are shown in Table 4.
The immune recovery also somewhat differed between
the groups. The NK-cell count was higher in the MM group,
reaching significance at 1 month and at 6 months after
auto-SCT. The CD19+ B-lymphocyte count was higher
among MM patients during the whole posttransplant
follow-up period. The immune recovery data are presented
in Table 5.
Long-term follow-up
The median (range) follow-up for patients remaining alive
was 55 (22-91) months in the NHL group and 61 (33-83)
months in the MM group in October 2019. In the MM group
111 patients (76%) had experienced a relapse or disease
progression and 42 patients (29%) had died. Disease relapse
had occurred in 46 NHL patients (34%) and 37 patients
(27%) had died, respectively (Fig. 1). All nonrelapse deaths
in our study were observed in patients older than 60 years
of age.
Fig. 1. PFS (A) and OS (B) of the MM and NHL patients. [Color figure can be viewed at wileyonlinelibrary.com]
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DISCUSSION
In this analysis based on the patient population of the pro-
spective multicenter GOA study, MM patients were com-
pared with NHL patients in regard to mobilization and
apheresis of CD34+ cells, cellular composition of blood grafts
infused after HDT, posttransplant recovery, and outcome.
MM patients mobilized CD34+ cells better and thus needed
less plerixafor. In addition, the blood grafts given to MM
patients contained more NK and CD19+ cells. Furthermore,
some differences in the hematologic and immune recovery
after auto-SCT were noted according to the diagnosis. NHL
patients carried a significantly higher risk of late NRM.
In this study 15% of the NHL patients were categorized
as poor mobilizers whereas only 3% of MM patients had a
peak B-CD34+ count of less than 20 × 106/L after mobiliza-
tion. The results are in line with a prior Finnish single-
center retrospective analysis9 in which 1.5% of the MM
patients and 17% of the NHL patients mobilized poorly. In a
large US retrospective study8 the mobilization failure rates
were 5% for MM and 26% for NHL patients; the majority of
the patients were mobilized with G-CSF alone. In a more
recent retrospective study,26 mobilization failed in 22% of
the lymphoma patients compared to 9% of the MM patients.
In contrast, in a German retrospective study10 the propor-
tion of poor mobilizers did not differ between chemo-
mobilized MM and NHL patients. In our study the
plerixafor usage was more common among NHL patients
(26% vs. 12%). The preemptive use of plerixafor27 may con-
tribute to the lower number of poor mobilizers in this study
than in previous reports.
In an Austrian prospective study the median CD34+
yield per apheresis procedure was 4.4 × 106/kg CD34+ cells
for MM patients and 3.5 × 106/kg for lymphoma patients28
and thus somewhat higher than in our study. In a Swedish
retrospective analysis the chemomobilized MM patients
recorded a median total yield of 11.2 × 106/kg compared to
significantly lower yields in different NHL subgroups.29 In
our study the apheresis yields were lower than those in the
Swedish study obviously due to the differences in mobiliza-
tion regimens used but also due to lower collection targets.
Chemomobilization has been shown to result in higher graft
CD34+ content in MM patients with fewer apheresis proce-
dures than G-CSF mobilization;23 this was also evident in
the whole GOA Study population. The more intense chemo-
therapy in the pretransplant phase may account for the
decreased ability to mobilize CD34+ cells in NHL. In addi-
tion, the use of large-volume leukapheresis may improve
CD34+ cell collection efficiency especially in poorly mobiliz-
ing patients.30 Data regarding the effect of large-volume
leukapheresis on more detailed graft cellular composition
are limited.31,32 In this study the apheresis procedures were
performed with standard-volume leukapheresis.
In our study with a roughly comparable infused graft
CD34+ content, the blood grafts contained a significantly
higher number of NK cells and CD19+ B cells in MM
patients. The number of CD19+ B lymphocytes in the grafts
was very low in both groups. The use of rituximab as a part
of the therapy in most NHL patients accounts for the
observed difference as rituximab kills B lymphocytes effec-
tively. However, when the grafts of chemomobilized
(CY plus G-CSF) MM patients and NHL patients were com-
pared, the CD3+, CD3+CD4+, CD3+CD8+, and NK-cell
counts were in fact lower among MM patients, reflecting
effective lymphocyte killing capacity of CY even with a mod-
erate dose. The differences in mobilizing therapy mainly
explain the observed differences. Previously we have found
that grafts mobilized with G-CSF alone contain significantly
more lymphocytes and NK cells than those mobilized with
low-dose CY plus G-CSF.33
Although there was no difference in the PLT count on
Day +15 after auto-SCT between the groups, the MM
patients recorded significantly higher PLT counts within a
year after auto-SCT. These observations suggest better graft
function in MM patients. An apparent reason is the more
intense chemotherapy given to the NHL patients before
mobilization and auto-SCT. The neutrophil engraftment was
faster among NHL patients in our study. The differences in
G-CSF use after the graft infusion mainly explain the
difference.
The blood NK-cell counts after auto-SCT were higher
among MM patients, reaching a significance at 1 and
6 months posttransplant. The CD3+ and CD3+CD8+ levels
were somewhat lower among NHL patients during the
follow-up, while there was no difference in the recovery of
blood CD3+CD4+ cells. Previously it has been shown that
graft CD3+, CD3+CD4+, and NK-cell counts correlate with
early NK-cell recovery in NHL patients.34 Since only the
NK-cell counts differed in the blood grafts in our study, this
cell population in the grafts might be responsible for the
observed difference in NK-cell recovery. The long-term
CD3+ and CD3+CD4+ cell recovery has been previously
shown to be slower among MM patients,35 corroborating
our findings of slower CD3+CD4+ and CD3+CD8+ lympho-
cyte recovery. All MM patients with analysis of immune
recovery belonged to MM-02 study, in which 10 mg/day
lenalidomide maintenance was started on Day + 100. This
treatment might have some effect on both immune recovery
and on neutrophil and PLT counts later.
The incidence of febrile neutropenia and bloodstream
infections during hospitalization following auto-SCT was
comparable between the groups, but NHL patients had
more ICU admissions. These results are in line with a previ-
ous prospective study from our institute in which 7.2% of
the NHL patients with febrile neutropenia and none of the
MM patients were treated at the ICU after auto-SCT.36
Severe sepsis was observed in 14% of the NHL patients
compared to only 2.8% of the MM patients. The predomi-
nance of Gram-positive bloodstream infections after auto-
SCT has also been observed previously.36,37 In our study the
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early NRM was absent among MM patients and was 1.5% in
the NHL group. Previous studies have shown slightly higher
rates of early mortality.38,39 Late (>100 days) NRM has been
shown to comprise mainly of secondary malignancies, infec-
tions, and cardiovascular disease in previous reports.40 In a
large Argentinian cohort39 the NRM was 2.9% in MM
patients and 8.1% in NHL patients at 3 years after auto-SCT,
corroborating our observations. With a relatively long
follow-up, we observed significantly higher risk of NRM in
NHL patients.
This is to the best of our knowledge the largest study in
an autologous setting evaluating blood graft cellular compo-
sition in detail. Thus, it allows comparison of mobilization
characteristics, graft composition, posttransplant recovery,
and complications in two major disease categories, where
auto-SCT is commonly applied. Furthermore, this study
represents a multicenter real-life situation at the present
time (2012-2016) as the study was observational.
There are differences in graft cellular composition,
hematologic and immune recovery posttransplant, risk of
nonrelapse death, and outcome between NHL and MM
patients. Further analyses are needed to evaluate the poten-
tial effects of different graft cellular components on post-
transplant recovery and outcome. These analyses should be
carried out separately for MM and NHL patients.
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